Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orthometrix's shock wave therapy:

This article was originally published in Clinica

Executive Summary

The US FDA has given Orthometrix approval to market its high-energy shock wave system for relieving chronic plantar fasciitis (foot pain). The Orbasone device, a small and compact product, creates shock waves by using a spark plug enclosed in a soft membrane-covered dome filled with water; the dome is placed against the heel. The physician-supervised treatment typically takes about 30-40 minutes. The American Podiatric Medical Association in 2000 said that 38.6 million people in the US suffered from plantar fasciitis, noted the White Plains, New York-based firm. The Orbasone system is already cleared for sale in Europe, Asia and Canada.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel